Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-29T14:42:10.199Z Has data issue: false hasContentIssue false
  • English
  • Français

Delirium, Antipsychotics and Death in the time of COVID-19

Published online by Cambridge University Press:  19 July 2023

R. Softic  and
N. Becarevic
R. Softic*
Affiliation:
of psychiatry, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina
N. Becarevic
Affiliation:
of psychiatry, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Delirium is an acute, transient, global organic disorder of CNS functioning resulting in impaired consciousness, attention, and other cognitive functions. Causes of delirium are multifactorial and can be unrecognized in 2/3 of cases. It is recommended to use as few psychotropic medications as possible because many of them can worsen delirium. Antipsychotics are not recommended as a drug of first choice.

Objectives

To present rate of delirium regarding to treatment and outcome.

Methods

A retrospective observational study was conducted in the department of consultative psychiatry of the University Clinical Center Tuzla during the one-year period of the COVID-19 pandemic.

Results

761 calls from different clinics of the University Clinical Center Tuzla were received in one year period. Delirium was diagnosed in 213 patients (28%). The total number of deaths was 147 (19.3%), the number of deaths in patients with delirium was 88 (41.3%). Antipsychotics were used in 137 (64%) patients with delirium. Death as an outcome was more common in patients treated with antipsychotics (64%) p˂ 0.05. The most used antipsychotic was Promazine 94 (44.1%). Number of deaths in patients with delirium treated with Promazine was 42 (44.7%) p ˂ 0.05.

Conclusions

In patients with delirium mortality is significantly higher in those treated with antipsychotics, especially when treated with Promazine. The choice of antipsychotic medications should be made according to pharmacological properties and the clinical context.

Disclosure of Interest

None Declared

Type
Abstract
Information
European Psychiatry , Volume 66 , Special Issue S1: Abstracts of the 31st European Congress of Psychiatry , March 2023 , pp. S400
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.